Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Lorviqua“
Suchtreffer
Begriffe & Kennungen
Lorviqua · 4.5 · In vitro, lorlatinib has a low potential to cause drug-drug interactions by induction of CYP1A2.
Eintrag öffnenLorviqua · 4.5 · Itraconazole, a strong inhibitor of CYP3A4/5, administered at oral doses of 200 mg once daily for 5 days, incr
Eintrag öffnenLorviqua · 4.5 · Lorlatinib 100 mg once daily for 15 days decreased AUCinf and Cmax of a single oral 100 mg dose of bupropion (
Eintrag öffnenLorviqua · 4.5 · Lorlatinib 100 mg once daily for 15 days decreased AUCinf and Cmax of a single oral 500 mg dose of acetaminoph
Eintrag öffnenLorviqua · 4.5 · Lorlatinib 100 mg once daily for 15 days decreased AUCinf and Cmax of a single oral 500 mg dose of tolbutamide
Eintrag öffnenLorviqua · 4.5 · Lorlatinib 100 mg once daily for 15 days decreased AUCinf and Cmax of a single oral dose of 60 mg fexofenadine
Eintrag öffnenLorviqua · 4.5 · P-glycoprotein substrates
Eintrag öffnenLorviqua · 4.5 · Pharmacokinetic interactions
Eintrag öffnenLorviqua · 4.5 · Rifampin, a strong inducer of CYP3A4/5, administered at oral doses of 600 mg once daily for 12 days, reduced t
Eintrag öffnenLorviqua · 4.5 · UGT substrates
Eintrag öffnenLorviqua · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenLorviqua · 4.8 Undesirable effects · 1
Eintrag öffnenLorviqua · 4.8 · 12 Respiratory, thoracic and mediastinal disorders Pneumonitisi Common 2.4 0.7 Gastrointestinal disorders Diar
Eintrag öffnenLorviqua · 4.8 · 13 hypertriglyceridaemia occurred in 59.8% and 47.2% of patients, respectively (see section 4.4). The median t
Eintrag öffnenLorviqua · 4.8 · Central nervous system effects CNS adverse reactions were primarily cognitive effects (27.4%), mood effects (2
Eintrag öffnenLorviqua · 4.8 · Description of selected adverse reactions
Eintrag öffnenLorviqua · 4.8 · Dose reductions due to adverse reactions occurred in 20.1% of patients receiving lorlatinib. The most common a
Eintrag öffnenLorviqua · 4.8 · Hypercholesterolaemia/hypertriglyceridaemia Adverse reactions of increase in serum cholesterol or triglyceride
Eintrag öffnenLorviqua · 4.8 · Hyperglycaemia Adverse reactions of hyperglycaemia were reported in 9.7% of patients from Study A, CROWN (B746
Eintrag öffnenLorviqua · 4.8 · Hypertension Adverse reactions of hypertension were reported in 14.8% of patients from Study A, CROWN (B746100
Eintrag öffnen